LONDON (Alliance News) - Venn Life Sciences Holdings PLC said Wednesday that it has signed a EUR2 million contract with an undisclosed European biotechnology company for a phase III study in rheumatology.
The study will cover multiple European countries and will run for over four years, starting immediately.
"The signing of this contract reinforces the continued success of our clinical and business development teams to win projects with leading international organisations. Venn has been steadily and continuously delivering on its strategy to win larger multi country scale contracts and to increase its footprint across Europe," said Chief Executive Officer Tony Richardson in a statement.
Shares in Venn Life Sciences are trading up 1.4% at 21.80 pence Wednesday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
